Fate Therapeutics (NASDAQ:FATE) is scheduled to announce its earnings results after the market closes on Monday, March 5th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.

Fate Therapeutics (NASDAQ:FATE) opened at $13.27 on Friday. The company has a current ratio of 7.21, a quick ratio of 7.21 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $676.53, a P/E ratio of -13.97 and a beta of 1.65. Fate Therapeutics has a 52-week low of $2.52 and a 52-week high of $14.03.

FATE has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Fate Therapeutics in a research report on Friday, November 10th. ValuEngine downgraded Fate Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Raymond James Financial restated a “buy” rating on shares of Fate Therapeutics in a research report on Tuesday, December 12th. Piper Jaffray Companies initiated coverage on Fate Therapeutics in a research report on Monday, December 18th. They issued an “overweight” rating and a $10.00 target price for the company. Finally, Wedbush restated an “outperform” rating and issued a $7.00 target price on shares of Fate Therapeutics in a research report on Monday, December 18th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Fate Therapeutics presently has an average rating of “Buy” and a consensus target price of $7.71.

A hedge fund recently bought a new stake in Fate Therapeutics stock. California State Teachers Retirement System bought a new position in Fate Therapeutics Inc (NASDAQ:FATE) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 67,500 shares of the biopharmaceutical company’s stock, valued at approximately $219,000. California State Teachers Retirement System owned 0.16% of Fate Therapeutics at the end of the most recent reporting period. 57.60% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Fate Therapeutics (FATE) Set to Announce Earnings on Monday” was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2018/03/03/fate-therapeutics-fate-set-to-announce-earnings-on-monday.html.

About Fate Therapeutics

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Earnings History for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.